JP2019511236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511236A5 JP2019511236A5 JP2018554069A JP2018554069A JP2019511236A5 JP 2019511236 A5 JP2019511236 A5 JP 2019511236A5 JP 2018554069 A JP2018554069 A JP 2018554069A JP 2018554069 A JP2018554069 A JP 2018554069A JP 2019511236 A5 JP2019511236 A5 JP 2019511236A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- car
- nucleic acid
- site
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 80
- 210000004027 cell Anatomy 0.000 claims description 57
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 56
- 150000007523 nucleic acids Chemical group 0.000 claims description 37
- 108091008874 T cell receptors Proteins 0.000 claims description 29
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 230000010354 integration Effects 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 230000006801 homologous recombination Effects 0.000 claims description 6
- 238000002744 homologous recombination Methods 0.000 claims description 6
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000000130 stem cell Anatomy 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 102000006707 alpha-beta T-Cell Antigen Receptors Human genes 0.000 claims 4
- 108010087408 alpha-beta T-Cell Antigen Receptors Proteins 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 108700019146 Transgenes Proteins 0.000 description 21
- 230000001225 therapeutic effect Effects 0.000 description 14
- 239000003937 drug carrier Substances 0.000 description 8
- 238000002659 cell therapy Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000003071 memory t lymphocyte Anatomy 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 210000002378 Th9 Anatomy 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323623P | 2016-04-15 | 2016-04-15 | |
| US62/323,623 | 2016-04-15 | ||
| US201662323675P | 2016-04-16 | 2016-04-16 | |
| US62/323,675 | 2016-04-16 | ||
| US201762461677P | 2017-02-21 | 2017-02-21 | |
| US62/461,677 | 2017-02-21 | ||
| US201762462243P | 2017-02-22 | 2017-02-22 | |
| US62/462,243 | 2017-02-22 | ||
| PCT/US2017/027601 WO2017180989A2 (en) | 2016-04-15 | 2017-04-14 | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511236A JP2019511236A (ja) | 2019-04-25 |
| JP2019511236A5 true JP2019511236A5 (OSRAM) | 2020-05-28 |
| JP7058223B2 JP7058223B2 (ja) | 2022-04-21 |
Family
ID=59285314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554069A Active JP7058223B2 (ja) | 2016-04-15 | 2017-04-14 | トランスジェニックｔ細胞及びキメラ抗原受容体ｔ細胞組成物及び関連方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11377637B2 (OSRAM) |
| EP (3) | EP3443075B1 (OSRAM) |
| JP (1) | JP7058223B2 (OSRAM) |
| KR (3) | KR20240000616A (OSRAM) |
| CN (1) | CN109790517B (OSRAM) |
| AU (1) | AU2017250769B2 (OSRAM) |
| BR (1) | BR112018071199A2 (OSRAM) |
| ES (2) | ES2933961T3 (OSRAM) |
| PT (2) | PT3443075T (OSRAM) |
| SG (1) | SG11201808831TA (OSRAM) |
| WO (1) | WO2017180989A2 (OSRAM) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10202101358XA (en) | 2015-01-26 | 2021-03-30 | Fate Therapeutics Inc | Methods and compositions for inducing hematopoietic cell differentiation |
| CA2989858A1 (en) * | 2015-06-17 | 2016-12-22 | The Uab Research Foundation | Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage |
| US11643668B2 (en) | 2015-06-17 | 2023-05-09 | The Uab Research Foundation | CRISPR/Cas9 complex for genomic editing |
| US10799535B2 (en) | 2015-10-05 | 2020-10-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
| JP6816133B2 (ja) * | 2015-10-05 | 2021-01-20 | プレシジョン バイオサイエンシズ，インク． | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| ES2953925T3 (es) * | 2015-11-04 | 2023-11-17 | Fate Therapeutics Inc | Ingeniería genómica de células pluripotentes |
| US10858628B2 (en) | 2015-11-04 | 2020-12-08 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| JP2019510503A (ja) * | 2016-04-07 | 2019-04-18 | ブルーバード バイオ， インコーポレイテッド | キメラ抗原受容体ｔ細胞組成物 |
| ES2933961T3 (es) | 2016-04-15 | 2023-02-15 | Memorial Sloan Kettering Cancer Center | Células T transgénicas y composiciones de células T de receptor de antígeno quimérico y métodos relacionados |
| BR112019007715A2 (pt) * | 2016-10-19 | 2019-07-09 | Cellectis Sa | inserção vetorizada de genes para terapia aprimorada com células imunes |
| GB2573664B (en) * | 2016-10-27 | 2022-09-28 | Intima Bioscience Inc | Viral methods of T cell therapy |
| EP3606550A2 (en) | 2017-04-03 | 2020-02-12 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
| WO2018204352A1 (en) | 2017-05-01 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| EP3638317A4 (en) | 2017-06-15 | 2021-03-17 | The Regents of The University of California | TARGETED NONVIRAL DNA INSERTIONS |
| US11053484B2 (en) | 2017-06-30 | 2021-07-06 | Precision Biosciences, Inc. | Genetically-modified T cells comprising a modified intron in the T cell receptor alpha gene |
| AU2018308923A1 (en) * | 2017-07-26 | 2020-03-12 | Cellectis | Methods of antigen-dependent chimeric antigen receptor (CAR) immune cell selection |
| KR102770787B1 (ko) | 2017-10-27 | 2025-02-19 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 내인성 t 세포 수용체의 표적화된 대체 |
| US11793867B2 (en) | 2017-12-18 | 2023-10-24 | Biontech Us Inc. | Neoantigens and uses thereof |
| BR112020016138A2 (pt) * | 2018-02-11 | 2020-12-15 | Memorial Sloan-Kettering Cancer Center | Receptores de células t não restritos ao hla e usos dos mesmos |
| SG11202007513PA (en) * | 2018-02-16 | 2020-09-29 | Kite Pharma Inc | Modified pluripotent stem cells and methods of making and use |
| US20200224160A1 (en) * | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| WO2019199689A1 (en) * | 2018-04-09 | 2019-10-17 | The Trustees Of The University Of Pennsylvania | Methods and compositions comprising a viral vector for expression of a transgene and an effector |
| IL304025A (en) | 2018-04-12 | 2023-08-01 | Prec Biosciences Inc | Optimized engineered nucleases with specificity for the human T cell receptor alpha constant region gene |
| WO2019204397A1 (en) * | 2018-04-17 | 2019-10-24 | Wake Forest University Health Sciences | Methods and compositions for th9 cell mediated cancer treatment |
| WO2019226998A1 (en) * | 2018-05-25 | 2019-11-28 | The Regents Of The University Of California | Genetic engineering of endogenous proteins |
| US20200054675A1 (en) | 2018-06-01 | 2020-02-20 | Washington University | Suppression of cytokine release syndrome in chimeric antigen receptor cell therapy |
| US12246067B2 (en) | 2018-06-19 | 2025-03-11 | Biontech Us Inc. | Neoantigens and uses thereof |
| CN110616188B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种通用型car-t细胞及其制备方法和应用 |
| US12359169B2 (en) | 2018-06-20 | 2025-07-15 | Shanghai Longyao Biotechnology Inc., Ltd. | Universal CAR-T cell and preparation method and use thereof |
| JP2021529559A (ja) * | 2018-07-03 | 2021-11-04 | ソティオ，リミティド ライアビリティ カンパニー | グルコース輸入を向上させるトランス代謝分子と組み合わせたキメラ受容体及びその治療的使用 |
| US20210381008A1 (en) * | 2018-07-26 | 2021-12-09 | Kyoto University | Method for producing foreign antigen receptor gene-introduced cell |
| NZ772146A (en) | 2018-08-14 | 2025-08-29 | Sotio Llc | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| CN120025452A (zh) | 2018-12-12 | 2025-05-23 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| EP3898946B1 (en) * | 2018-12-19 | 2023-02-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors |
| WO2020160489A1 (en) * | 2019-02-01 | 2020-08-06 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| CA3130489A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| JP7650809B2 (ja) * | 2019-03-06 | 2025-03-25 | レンティジェン・テクノロジー・インコーポレイテッド | 自己駆動型キメラ抗原受容体を用いてがんを処置するための組成物および方法 |
| AU2020253023B2 (en) | 2019-03-29 | 2022-07-14 | F. Hoffmann-La Roche Ag | Method for the generation of an FcRn expressing cell by targeted integration of multiple expression cassettes in a defined organization |
| CA3135224A1 (en) * | 2019-04-11 | 2020-10-15 | Fate Therapeutics, Inc. | Cd3 reconstitution in engineered ipsc and immune effector cells |
| JP7754722B2 (ja) | 2019-05-01 | 2025-10-15 | ジュノー セラピューティクス インコーポレイテッド | 改変されたｃｄ２４７遺伝子座からキメラ受容体を発現する細胞、関連ポリヌクレオチド、および方法 |
| JP2022533128A (ja) * | 2019-05-16 | 2022-07-21 | ユニバーシティ オブ ワシントン | Ｃａｒ ｔ細胞のｌｏｃｋｒ媒介性動員 |
| MX2021015540A (es) * | 2019-06-19 | 2022-02-10 | Hoffmann La Roche | Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida. |
| CN115298208A (zh) | 2019-07-19 | 2022-11-04 | 纪念斯隆-凯特琳癌症中心 | 免疫治疗用融合多肽 |
| EP4003407A1 (en) | 2019-07-23 | 2022-06-01 | Mnemo Therapeutics | Immune cells defective for suv39h1 |
| CN117925528A (zh) * | 2019-07-24 | 2024-04-26 | 浙江煦顼技术有限公司 | 具有增强记忆t细胞表型的修饰t细胞 |
| CA3151690A1 (en) * | 2019-09-23 | 2021-04-01 | Beau WEBBER | Genetically-edited immune cells and methods of therapy |
| WO2021061946A2 (en) * | 2019-09-25 | 2021-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | A promoter specific for non-pigmented ciliary epithelial cells |
| SG10201909544YA (en) * | 2019-10-11 | 2021-05-28 | Nat Univ Singapore | Genetically Modified T Cells And Uses Thereof |
| MX2022005817A (es) * | 2019-11-13 | 2022-06-08 | Crispr Therapeutics Ag | Metodos de fabricacion de linfocitos t-car. |
| BR112022009152A2 (pt) * | 2019-11-13 | 2022-07-26 | Crispr Therapeutics Ag | Processo de fabricação para preparar células t expressando receptores de antígenos quiméricos |
| CN113122576A (zh) * | 2019-12-31 | 2021-07-16 | 博雅辑因（北京）生物科技有限公司 | 一种通用型truck-t细胞、其制备方法以及用途 |
| JP2023510238A (ja) * | 2020-01-02 | 2023-03-13 | エディティ セラピューティクス リミテッド | 送達組成物および方法 |
| CA3171369A1 (en) * | 2020-02-28 | 2021-09-02 | Wisconsin Alumni Research Foundation | Nonviral generation of genome edited chimeric antigen receptor t cells |
| EP4121453A2 (en) * | 2020-03-20 | 2023-01-25 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| GB202006903D0 (en) * | 2020-05-11 | 2020-06-24 | Adaptimmune Ltd | Modified iPSCs |
| AU2021300112A1 (en) * | 2020-06-29 | 2023-02-16 | Cell Medica, Inc. | Methods and compositions for the reduction of chimeric antigen receptor tonic signaling |
| WO2022011065A1 (en) * | 2020-07-07 | 2022-01-13 | The Nemours Foundation | Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer |
| CN116096864A (zh) | 2020-07-30 | 2023-05-09 | 居里研究所 | Socs1缺陷的免疫细胞 |
| CN116323920A (zh) * | 2020-08-07 | 2023-06-23 | 荷兰商新基因治疗公司 | 富集基因工程t细胞的方法 |
| US20230364137A1 (en) * | 2020-09-30 | 2023-11-16 | Vor Biopharma Inc. | Chimeric antigen receptor expression systems |
| CA3200741A1 (en) * | 2020-12-01 | 2022-06-09 | Daniel Zurr | Methods for enhancing therapeutic efficacy of isolated cells for cell therapy |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| EP4019538A1 (en) * | 2020-12-22 | 2022-06-29 | Charité - Universitätsmedizin Berlin | Reprogramming immune cells by targeted integration of zeta-deficient chimeric antigen receptor transgenes |
| IL305804A (en) | 2021-03-11 | 2023-11-01 | Inst Curie | Transmembrane neoantigenic peptides |
| JP2024510981A (ja) | 2021-03-11 | 2024-03-12 | ムネモ・セラピューティクス | 腫瘍ネオ抗原ペプチド及びその使用 |
| IL305810A (en) | 2021-03-11 | 2023-11-01 | Mnemo Therapeutics | Tumor neoantigenic peptides |
| JP2024517968A (ja) * | 2021-05-14 | 2024-04-23 | アピア バイオ， インコーポレイテッド | 幹細胞からの操作されたｔ細胞の産生 |
| WO2023057285A1 (en) | 2021-10-06 | 2023-04-13 | Miltenyi Biotec B.V. & Co. KG | Method for targeted gene insertion into immune cells |
| PE20241173A1 (es) | 2021-10-14 | 2024-05-28 | Arsenal Biosciences Inc | Celulas inmunitarias que tienen arnhc coexpresados y sistemas de compuerta logica |
| CN118871572A (zh) * | 2021-10-14 | 2024-10-29 | 阿彼雅生物有限公司 | 使用多种t细胞受体对干细胞t细胞进行工程化 |
| US20250000907A1 (en) * | 2021-11-22 | 2025-01-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Engineered immune cells with reduced sirt6 expression |
| JP2025501272A (ja) | 2021-12-28 | 2025-01-17 | ムネモ・セラピューティクス | 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞 |
| US20250115916A1 (en) | 2022-01-21 | 2025-04-10 | Mnemo Therapeutics | Modulation of suv39h1 expression by rnas |
| CN115304679B (zh) * | 2022-01-21 | 2024-07-16 | 郑州大学第一附属医院 | 一种促进t细胞分化的限制型car及其应用 |
| WO2023178227A2 (en) * | 2022-03-17 | 2023-09-21 | University Of Florida Research Foundation, Incorporated | Chimeric lactate receptor engineered t cells |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2023225670A2 (en) * | 2022-05-20 | 2023-11-23 | Tome Biosciences, Inc. | Ex vivo programmable gene insertion |
| WO2024039576A2 (en) | 2022-08-19 | 2024-02-22 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| WO2024050551A2 (en) * | 2022-09-02 | 2024-03-07 | Oncosenx, Inc. | Compositions and methods for in vivo expression of chimeric antigen receptors |
| BE1031219B1 (fr) | 2022-12-28 | 2024-07-29 | Quidditas Sa | Composition, cellules immunitaires la comprenant et utilisation de ces dernières |
| WO2025096560A1 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025096594A2 (en) * | 2023-10-30 | 2025-05-08 | Allogene Therapeutics, Inc. | Cells expressing anti-cd19 chimeric antigen receptors and methods of use thereof |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
| WO2025213167A1 (en) * | 2024-04-05 | 2025-10-09 | Roswell Park Cancer Institute Corporation | Complement signaling as a t-cell checkpoint in the tumor microenvironment (tme) |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| AU2002246733B2 (en) | 2000-12-19 | 2007-09-20 | Altor Bioscience Corporation | Transgenic animals comprising a humanized immune system |
| DE60106469T2 (de) | 2001-12-22 | 2005-10-13 | 4-Antbody AG | Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen |
| CN100360565C (zh) | 2001-12-22 | 2008-01-09 | 4-抗体股份公司 | 制备脊椎动物淋巴细胞和生产结合蛋白的方法 |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| WO2005026718A1 (en) | 2003-08-28 | 2005-03-24 | Five Prime Therapeutics, Inc. | Stem cell libraries |
| US20110213288A1 (en) | 2007-04-23 | 2011-09-01 | The Board Of Regents, The University Of Texas System | Device And Method For Transfecting Cells For Therapeutic Uses |
| US9051391B2 (en) | 2007-06-11 | 2015-06-09 | Takara Bio Inc. | Method for expression of specific gene |
| ES2627552T3 (es) | 2008-12-04 | 2017-07-28 | Sigma Aldrich Company | Edición de genoma en ratas usando nucleasas con dedos de cinc |
| AU2010275432A1 (en) | 2009-07-24 | 2012-02-02 | Sigma-Aldrich Co. Llc. | Method for genome editing |
| US9273283B2 (en) | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| HRP20190556T1 (hr) | 2009-11-03 | 2019-06-14 | City Of Hope | SKRAĆENI OBLIK RECEPTORA EPIDERMALNOG FAKTORA RASTA ZA (EGFRt) ODABIR TRANSDUCIRANIH T-STANICA |
| US8956828B2 (en) * | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| AU2011281062B2 (en) | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| PE20141521A1 (es) | 2011-08-23 | 2014-10-25 | Roche Glycart Ag | Moleculas biespecificas de union a antigeno activadoras de celulas t |
| ES2828663T3 (es) | 2012-04-18 | 2021-05-27 | Univ Leland Stanford Junior | Dirección genética no disruptiva |
| CN111676196A (zh) | 2012-05-25 | 2020-09-18 | 塞勒克提斯公司 | 工程化异体和免疫抑制耐受性t细胞的方法 |
| MY189533A (en) | 2012-05-25 | 2022-02-16 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
| ES2824024T3 (es) * | 2012-10-10 | 2021-05-11 | Sangamo Therapeutics Inc | Compuestos modificadores de células T y usos de los mismos |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| KR102332790B1 (ko) | 2013-02-15 | 2021-12-01 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 키메라 항원 수용체 및 이의 이용 방법 |
| US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| JP6346266B2 (ja) | 2013-03-21 | 2018-06-20 | サンガモ セラピューティクス， インコーポレイテッド | 操作されたジンクフィンガータンパク質ヌクレアーゼを使用するｔ細胞受容体遺伝子の標的化された破壊 |
| CA3185368A1 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t cells derived from pluripotent stem cells |
| CA2909701C (en) | 2013-04-17 | 2022-12-06 | Baylor College Of Medicine | Immunosuppressive tgf-.beta. signal converter |
| EP2997134B1 (en) | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| ES2883131T3 (es) | 2013-05-29 | 2021-12-07 | Cellectis | Métodos para la modificación de células T para inmunoterapia utilizando el sistema de nucleasa CAS guiado por ARN |
| EP3309248B1 (en) | 2013-05-29 | 2021-06-09 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| AU2015233347A1 (en) | 2014-03-21 | 2016-09-08 | Cellectis | Engineering mammalian genome using DNA-guided Argonaute interference systems (DAIS) |
| CN106459918A (zh) | 2014-04-24 | 2017-02-22 | 得克萨斯州大学系统董事会 | 施加诱导多能干细胞产生过继细胞疗法产品 |
| WO2015172147A1 (en) | 2014-05-09 | 2015-11-12 | Research Foundation Of The City University Of New York | Tcr(alpha)-lcr-derived gene regulatory cassettes |
| WO2015188065A1 (en) * | 2014-06-05 | 2015-12-10 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease design |
| JP6688231B2 (ja) | 2014-06-06 | 2020-04-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 標的遺伝子座を修飾するための方法及び組成物 |
| RU2017113134A (ru) | 2014-09-19 | 2018-10-19 | Регенерон Фармасьютикалз, Инк. | Химерные антигенные рецепторы |
| WO2016081924A1 (en) | 2014-11-20 | 2016-05-26 | Duke University | Compositions, systems and methods for cell therapy |
| BR112017020750A2 (pt) | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
| WO2016166268A1 (en) | 2015-04-17 | 2016-10-20 | Cellectis | Engineering animal or plant genome using dna-guided argonaute interference systems (dais) from mesophilic prokaryotes |
| KR102012119B1 (ko) * | 2015-05-15 | 2019-08-19 | 오루 카약 인코포레이티드 | 큰 조종석을 갖는 접이식 카약 |
| AU2016291778B2 (en) | 2015-07-13 | 2021-05-06 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| WO2017023803A1 (en) | 2015-07-31 | 2017-02-09 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| US10799535B2 (en) * | 2015-10-05 | 2020-10-13 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human T cell receptor alpha constant region gene |
| JP6816133B2 (ja) * | 2015-10-05 | 2021-01-20 | プレシジョン バイオサイエンシズ，インク． | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| US10858628B2 (en) | 2015-11-04 | 2020-12-08 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| ES2953925T3 (es) | 2015-11-04 | 2023-11-17 | Fate Therapeutics Inc | Ingeniería genómica de células pluripotentes |
| US20210206826A1 (en) | 2015-11-19 | 2021-07-08 | The Regents Of The University Of California | Conditionally repressible immune cell receptors and methods of use thereof |
| EP3426690A4 (en) | 2016-03-11 | 2019-10-09 | Bluebird Bio, Inc. | GENOMEDITIZED IMMUNEFFECTOR CELLS |
| EP3430136A2 (en) | 2016-03-19 | 2019-01-23 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulated expansion thereof |
| JP2019510503A (ja) | 2016-04-07 | 2019-04-18 | ブルーバード バイオ， インコーポレイテッド | キメラ抗原受容体ｔ細胞組成物 |
| ES2933961T3 (es) | 2016-04-15 | 2023-02-15 | Memorial Sloan Kettering Cancer Center | Células T transgénicas y composiciones de células T de receptor de antígeno quimérico y métodos relacionados |
-
2017
- 2017-04-14 ES ES17735670T patent/ES2933961T3/es active Active
- 2017-04-14 KR KR1020237042980A patent/KR20240000616A/ko active Pending
- 2017-04-14 PT PT177356706T patent/PT3443075T/pt unknown
- 2017-04-14 KR KR1020187032919A patent/KR102437015B1/ko active Active
- 2017-04-14 EP EP17735670.6A patent/EP3443075B1/en active Active
- 2017-04-14 WO PCT/US2017/027601 patent/WO2017180989A2/en not_active Ceased
- 2017-04-14 BR BR112018071199-3A patent/BR112018071199A2/pt active Search and Examination
- 2017-04-14 EP EP22197444.7A patent/EP4180519B1/en active Active
- 2017-04-14 SG SG11201808831TA patent/SG11201808831TA/en unknown
- 2017-04-14 US US16/091,494 patent/US11377637B2/en active Active
- 2017-04-14 AU AU2017250769A patent/AU2017250769B2/en active Active
- 2017-04-14 JP JP2018554069A patent/JP7058223B2/ja active Active
- 2017-04-14 CN CN201780037351.1A patent/CN109790517B/zh active Active
- 2017-04-14 PT PT221974447T patent/PT4180519T/pt unknown
- 2017-04-14 ES ES22197444T patent/ES3039670T3/es active Active
- 2017-04-14 EP EP25181439.8A patent/EP4628587A2/en active Pending
- 2017-04-14 KR KR1020227029151A patent/KR102614675B1/ko active Active
-
2022
- 2022-05-25 US US17/824,650 patent/US12404316B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511236A5 (OSRAM) | ||
| KR102691932B1 (ko) | 마이크로RNA-적응 shRNA(shRNAmiR)를 포함하는 유전자-변형 면역 세포 | |
| US11981721B2 (en) | Transposon-based transfection system for primary cells | |
| KR102186180B1 (ko) | 면역 기능 제어 인자를 발현하는 면역 담당 세포 및 발현 벡터 | |
| JP7005346B2 (ja) | 養子細胞免疫療法の有効性を増強させるための組成物および方法 | |
| JP6161098B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| Gowrishankar et al. | Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells | |
| IL274179B2 (en) | Targeted replacement of endogenous T cell receptors | |
| JP2022164858A (ja) | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 | |
| KR20200015939A (ko) | 신규의 세포 태그의 발현 | |
| KR20170108946A (ko) | Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도 | |
| CA2978171A1 (en) | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof | |
| CN106535925A (zh) | 基于car的免疫治疗 | |
| JP2021518747A (ja) | Ｒｎａ不安定化エレメントを使用した遺伝子発現の調整 | |
| JP2019533463A (ja) | 遺伝子組換えにより内在性ｆｏｘｐ３遺伝子の発現が安定化されたｃｄ４ ｔ細胞を使用した自己免疫疾患の治療方法 | |
| Reuter et al. | Immunostimulation by OX40 ligand transgenic Ewing sarcoma cells | |
| US11098283B2 (en) | T cells modified to overexpress c-Myb | |
| JP6723164B2 (ja) | Ｔ細胞集団の改変方法 | |
| Alsaieedi et al. | Tracing the development of CAR-T cell design: from concept to next-generation platforms | |
| US20230279352A1 (en) | Methods for generating primary immune cells | |
| KR20200129959A (ko) | 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도 | |
| WO2010114129A1 (ja) | Ｔ細胞レセプター及び該レセプターをコードする核酸 | |
| Xue et al. | Anti-tumour research of recombinant BCG using BZLF1 and hGM-CSF fusion genes | |
| US20250270546A1 (en) | Guide rnas and uses thereof | |
| Yang et al. | Analysis of the complex genomic structure of Bcl-x and its relationship to Bcl-xγ expression after CD28-dependent costimulation |